Shanghai Fudan Zhangjiang Bio Pharmaceutical : INDICATIVE ANNOUNCEMENT ON OBTAINING DRUG REGISTRATION CERTIFICATE (PARECOXIB SODIUM)

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

INDICATIVE ANNOUNCEMENT ON OBTAINING DRUG REGISTRATION CERTIFICATE

This announcement is made by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.* (the "Company", together with its subsidiaries, the "Group") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that as at the date of this announcement, Parecoxib Sodium for Injection (specifications: 20mg and 40mg) (the "Drug") , an anti-inflammatory and analgesic product of Taizhou Fudan-Zhangjiang Pharmaceutical Co.,Ltd* (泰州復旦張江藥業有限公司) ("Taizhou Fudan-Zhangjiang"), a subsidiary of the Company, has obtained the Drug Registration Certificate which approval numbers are NMPN H20213127 and NMPN H20213128 issued by National Medical Products Administration ("NMPA"). The Drug was approved for sale according to the evaluation standard consistent with the quality and efficacy of the original drug. Taizhou Fudan-Zhangjiang will proceed the subsequent production and sales of the Drug as soon as possible.

As the first generic drug of the Group which can be produced with Hemoporfin (复美达®, FuMeiDa) for the treatment of port wine stain on the same production line, the approval for sale of the Drug will further diversify the product portfolio of the Group as well as exploit the capacity of Taizhou Fudan-Zhangjiang's production lines. It will bring a positive impact on the operation and development of the Group in the future.

The Drug is a selective oxidase-2 (Cyclooxygenase-2, COX-2) inhibitor, which is indicated for the short-term treatment of postoperative pain. According to foreign literature reports, it has clinically used in dentistry, orthopaedics, gynecology, and coronary artery bypass grafting. The Drug has the characteristics of rapid and extended potency of pain relief, high gastrointestinal safety, no additional cardiovascular risk and can significantly reduce the amount of postoperative opioids. It is regarded as one of the basic drugs for clinical multimodal analgesia. The Parecoxib Sodium for Injection was firstly approved for sale in China in 2008. At present, it belongs to Category B Drugs in the Drug Catalogue of National Basic Medical insurance, Industrial Injury Insurance and Maternity Insurance.

As of the date of this announcement, the cumulative R&D cost of the Drug is approximately RMB20 million.

The Drug has not been launched for sale at present. Subject to factors such as future policy changes, market demand and horizontal competition, the future sales for the Drug have uncertainty. Investors are advised to be cautious of investment risks.

By order of the Board

Wang Hai Bo

Chairman

As at the date on the publication of this announcement, the Board comprises:

Mr. Wang Hai Bo (Executive Director)

Mr. Su Yong (Executive Director)

Mr. Zhao Da Jun (Executive Director)

Mr. Shen Bo (Non-executive Director)

Ms. Yu Xiao Yang (Non-executive Director)

Mr. Zhou Zhong Hui (Independent Non-executive Director)

Mr. Lam Yiu Kin (Independent Non-executive Director)

Mr. Xu Qing (Independent Non-executive Director)

Mr. Yang Chun Bao (Independent Non-executive Director)

Shanghai, the PRC

25 February 2021

* For identification purpose only